A nine-gene signature predicting clinical outcome in cutaneous melanoma

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 2, 2013, Pages 249-258

  Brunner, G ^a   Reitz, M ^b   Heinecke, A ^c   Lippold, A ^a   Berking, C ^d   Suter, L ^a   Atzpodien, J ^a  

^a Skin Cancer Center Hornheide Münster   (Germany)

^b European Institute for Tumor Immunology and Prevention   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Gene expression profiling; Gene signature; Melanoma; Prognosis; RT PCR

Indexed keywords

CYTOKERATIN 9; DERMCIDIN; MAMMAGLOBIN A; TUMOR MARKER;

ADULT; AGED; AMERICAN JOINT COMMITTEE ON CANCER STAGING; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLLAGEN TYPE 6 ALPHA 6 GENE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DERMCIDIN GENE; DISTANT METASTASIS FREE SURVIVAL; ESOPHAGEAL CANCER RELATED GENE 2; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION RISK SCORE; GENE IDENTIFICATION; GENETIC CORRELATION; HAIRY AND ENHANCER OF SPLIT 6 GENE; HUMAN; HUMAN TISSUE; KELCH REPEAT AND BTB DOMAIN CONTAINING 10 GENE; KERATIN 9 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROLACTIN INDUCED PROTEIN GENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; SECRETOGLOBIN FAMILY 1D MEMBER 2 GENE; SECRETOGLOBIN FAMILY 2A MEMBER 2 GENE; STROMA; SURVIVAL RATE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874980924     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1322-z     Document Type: Article

References (37)

1. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
2. Bittner M, Meltzer P, Chen Y et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540
3. Braeuer RR, Zigler M, Villares GJ et al (2011) Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol 21:83-85
4. Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, Biess B, Suter L, Atzpodien J (2008) Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm 23:451-459
5. Chen H-Y, Sung-Liang Y, Chun-Houh C et al (2007) A five-gene signature and clinical outcome in non-small cell lung cancer. N Engl J Med 356:11-20
6. Cheng X, Shen Z, Yin L, Lu SH, Cui Y (2009) ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J Biol Chem 284:30897-30906
7. Conway C, Mitra A, Jewell R et al (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939-6946
8. Crowley NJ, Seigler HF (1990) Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 212:173-177
9. Fitzgerald J, Rich C, Zhou FH, Hansen U (2008) Three novel collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). J Biol Chem 283:20170-20180
10. Gimotty PA, Botbyl J, Soong SJ, Guerry D (2005) A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 23:8065-8075
11. Gould Rothberg BE, Rimm DL (2010) Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 130:1971-1987
12. Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 20:309-322
13. Haqq C, Nosrati M, Sudilovsky D et al (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-6097
14. Hassan MI, Waheed A, Yadav S et al (2009) Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci 66:447-459
15. Hoek KS (2007) DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20:466-484
16. Jaeger J, Koczan D, Thiesen H-J, Ibrahim SM, Gross G, Spang R, Kunz M (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13:806-815
17. Kaifi JT, Rawnaq T, Schurr PG et al (2007) Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer. Am J Surg 194:380-384
18. Kashani-Sabet M, Venna S, Nosrati M et al (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987-6992
19. Katoh M, Katoh M (2007) Integrative genomic analyses on HES/HEY family: notch-independent HES1, HES3 transcription in undifferentiated ES cells, and notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 31:461-466
20. Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13:1033-1067
21. Malesh K, Parmar B, Machin D (2004) Survival analysis, a practical approach. Wiley, Chichester, p 154
22. Meyer S, Fuchs TJ, Bosserhoff AK et al (2012) A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS ONE 7:e38222
23. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
24. Pfaff Smith A, Hoek K, Becker D (2005) Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4:1018-1029
25. Porter D, Weremowicz S, Chin K et al (2003) A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci USA 100:10931-10936
26. Ren S, Liu S, Howell P, Xi Y, Enkemann SA, Ju J, Riker AI (2008) The impact of genomics in understanding human melanoma progression and metastasis. Cancer Control 15:202-215
27. Riker AI, Enkemann SA, Fodstad O et al (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1:13
28. Roberts L, Bowers J, Sensinger K, Lisowski A, Getts R, Anderson MG (2009) Identification of methods for use of formalin-fixed, paraffin-embedded samples in RNA expression profiling. Genomics 94:341-348
29. Shentu Y, Xie M (2010) A note on dichotomization of continuous response variable in the presence of contamination and model misspecification. Stat Med 29:2200-2214
30. Sloan DD, Nicholson B, Urquidi V, Goodison S (2004) Detection of differentially expressed genes in an isogenic breast metastasis model using RNA arbitrarily primed-polymerase chain reaction coupled with array hybridization (RAP-array). Am J Pathol 164:315-323
31. Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7:545-553
32. Stewart GD, Skipworth RJ, Pennington CJ, Lowrie AG, Deans DA, Edwards DR, Habib FK, Riddick AC, Fearon KC, Ross JA (2008) Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. Br J Cancer 99:126-132
33. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701
34. Van de Vijver MJ, He YD, van't Veer LJ et al (2002) A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
35. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG (2008) Pro-neural transcription factors as cancer markers. BMC Med Genomics 19:17
36. Winnepenninckx V, Lazar V, Michiels S et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-482
37. Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knüchel R, Dahl E (2006) Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 6:88